Interestingly, human patients harbouring loss of function mutations PCYT2 have recently been found to develop complex hereditary spastic paraplegia (HSP) and a broad ataxia-spasticity condition and implicate disturbed neuronal phospholipid metabolism as a key pathological feature [83–85]. Here, PCYT2 is linked to hereditary spastic paraplegia.